Sudoscan in ATTRv Amyloidosis: A Potential Marker of Disease Progression?
Sudoscan may represent a reliable marker of dysautonomia in ATTRv amyloidosis, displaying a potential role as a marker of both disease severity and progression. It could, therefore, serve as an outcome measure in future clinical trials. In addition, feet ESC seems to be a significant, independent predictor of autonomic dysfunction.
Authors
- Francesca Vitali (ORCID: https://orcid.org/0000-0002-3177-1575)
- Marco Luigetti (ORCID: https://orcid.org/0000-0001-7539-505X)
- Valeria Guglielmino (ORCID: https://orcid.org/0000-0002-9049-5988)
- Ângela Romano (ORCID: https://orcid.org/0000-0002-2061-1509)
- Guido Primiano (ORCID: https://orcid.org/0000-0001-7616-7008)
- Andrea Di Paolantonio (ORCID: https://orcid.org/0000-0002-0051-6993)
- Maria Ausilia Sciarrone (ORCID: https://orcid.org/0000-0002-1490-0320)
- Giovanni Siconolfi
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Agostino Gemelli University Polyclinic (IT)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1007/s40120-025-00721-1
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00